Third Arc Bio vs Vivtex
Side-by-side comparison of AI visibility scores, market position, and capabilities
Raised $52M Series A extension (Feb 2026) from a16z as new investor — total $217M. ARC101 (bispecific T cell engager, CLDN6+) in Phase 1 solid tumors. Platform spans oncology and autoimmune.
About
Third Arc Bio raised a $52 million Series A extension in February 2026 with Andreessen Horowitz as a new investor, building on its prior $165 million Series A to reach $217 million in total financing. The company develops multifunctional antibodies — protein therapeutics that combine multiple mechanisms of action in a single molecule — with its lead program ARC101 being a bispecific T cell engager targeting CLDN6 in solid tumors, currently in Phase 1 clinical trials.
Signed $2.1B Novo Nordisk collaboration (Feb 2026). Platform enables oral delivery of proteins and peptides (historically injection-only). MIT Langer lab spinout.
About
Vivtex is an MIT Langer Laboratory spinout that has developed a drug delivery platform enabling oral administration of biologics — proteins, peptides, and other large molecules — that have historically required injection because they are degraded by stomach acid and too large to absorb through the intestinal wall. In February 2026, Vivtex signed a $2.1 billion collaboration agreement with Novo Nordisk for the development of oral formulations of biologic drugs in obesity, diabetes, and metabolic disease.
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Capabilities
Integrations
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.